Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joon Ho Moon

Showing results (271-280 of 280) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 280 results.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Blood Cell Therapy|December 9, 2024
Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021Minako Iida, Aloysius Ho, Xiao Jun Huang, et al.
Blood Cell Therapy|September 10, 2025
Corrigendum to: Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021 [Blood Cell Therapy. 2024; 7(4): 129-137. doi:10.31547/bct-2024-020]Minako Iida, Aloysius Ho, Xiao Jun Huang, et al.
Haematologica|May 9, 2024
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donorsYoshiko Atsuta, Helen Baldomero, Daniel Neumann, et al.
Blood|June 13, 2015
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemiaDae-Young Kim, Young-Don Joo, Sung-Nam Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Clonal hematopoiesis is associated with risk of severe Covid-19Kelly L Bolton, Youngil Koh, Michael B Foote, et al.
Nature Communications|October 14, 2021
Clonal hematopoiesis is associated with risk of severe Covid-19Kelly L Bolton, Youngil Koh, Michael B Foote, et al.
Blood Research|February 4, 2025
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questionsSung-Hoon Jung, Youngil Koh, Min Kyoung Kim, et al.
Acta Haematologica|September 26, 2018
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple MyelomaGyeong-Won Lee, Sung Woo Park, Se-Il Go, et al.
Oncotarget|April 14, 2017
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myelomaMin Kyoung Kim, Kihyun Kim, Chang-Ki Min, et al.
Pageof 28

Showing results (271-280 of 280) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 280 results.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Blood Cell Therapy|December 9, 2024
Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021Minako Iida, Aloysius Ho, Xiao Jun Huang, et al.
Blood Cell Therapy|September 10, 2025
Corrigendum to: Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021 [Blood Cell Therapy. 2024; 7(4): 129-137. doi:10.31547/bct-2024-020]Minako Iida, Aloysius Ho, Xiao Jun Huang, et al.
Haematologica|May 9, 2024
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donorsYoshiko Atsuta, Helen Baldomero, Daniel Neumann, et al.
Blood|June 13, 2015
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemiaDae-Young Kim, Young-Don Joo, Sung-Nam Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Clonal hematopoiesis is associated with risk of severe Covid-19Kelly L Bolton, Youngil Koh, Michael B Foote, et al.
Nature Communications|October 14, 2021
Clonal hematopoiesis is associated with risk of severe Covid-19Kelly L Bolton, Youngil Koh, Michael B Foote, et al.
Blood Research|February 4, 2025
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questionsSung-Hoon Jung, Youngil Koh, Min Kyoung Kim, et al.
Acta Haematologica|September 26, 2018
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple MyelomaGyeong-Won Lee, Sung Woo Park, Se-Il Go, et al.
Oncotarget|April 14, 2017
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myelomaMin Kyoung Kim, Kihyun Kim, Chang-Ki Min, et al.
Pageof 28